AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization

ACS Chemical Biology

Volumn 4, Issue 3, 2009, Pages 199-208

  Jones, Jeremy O ^a   An, W Frank ^b   Diamond, Marc I ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; LIGAND; LUCIFERASE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONFORMATIONAL TRANSITION; CORRELATION ANALYSIS; CYTOPLASM; EMBRYO; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HORMONE BINDING; HUMAN; HUMAN CELL; MICROSCOPY; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; TRANSCRIPTION INITIATION;

EID: 65249138882     PISSN: 15548929     EISSN: None     Source Type: Journal    
DOI: 10.1021/cb900024z     Document Type: Article

References (35)

1. Katzenellenbogen, J. A., and Katzenellenbogen, B. S. (1996) Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses, Chem. Biol. 3, 529-536.
2. Gelmann, E. P. (2002) Molecular biology of the androgen receptor,J. Clin. Oncol. 20, 3001-3015.
3. Chen, Y., Sawyers, C. L., and Scher, H. I. (2008) Targeting the androgen receptor pathway in prostate cancer, Curr. Opin. Pharmacol. 8, 440-448.
4. Craft, N., Shostak, Y., Carey, M., and Sawyers, C. L. (1999) A mechanism for hormone-independent prostate cancerthrough modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase, Nat. Med. 5, 280-285.
5. Klocker, H., Culig, Z., Hobisch, A., Cato, A. C., and Bartsch, G. (1994) Androgen receptor alterations in prostatic carcinoma, Prostate 25, 266-273.
6. Yeh, S., Lin, H. K., Kang, H. Y., Thin, T. H., Lin, M. F., and Chang, C. (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells, Proc. Natl. Acad. Sci. U.SA. 96, 5458-5463.
7. Ueda, T., Bruchovsky, N., and Sadar, M. D. (2002) Activation of the androgen receptor N-terminaldomain by interleukin-6 viaMAPKand STAT3 signal transduction pathways, J. Biol. Chem. 277, 7076-7085.
8. Cardozo, C. P., Michaud, C., Ost, M. C., Fliss, A. E., Yang, E., Patterson, C., Hall, S. J., and Caplan, A. J. (2003) C-terminal Hspinteracting protein slows androgen receptorsynthesis and reduces its rate of degradation, Arch. Biochem. Biophys. 410,134-140.
9. Georget, V., Terouanne, B., Nicolas, J. C., and Sultan, C. (2002) Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor, Biochemistry 41,11824-11831.
10. Schaufele, F., Carbonell, X., Guerbadot, M., Borngraeber, S., Chapman, M. S., Ma, A. A., Miner, J. N., and Diamond, M. I. (2005) The structural basis of androgen receptor activation: intramolecularand intermolecular amino-carboxy interactions, Proc. Natl. Acad. Sci. U.S.A. 102, 9802-9807.
11. Jones, J. O., and Diamond, M. I. (2008) A cellular conformation-based screen forandrogen receptor inhibitors, ACSChem. Biol. 3, 412-418.
12. Poletti, A. (2004) The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons, Front. Neuroendocrinol. 25, 1-26.
13. Tyagi, R. K., Lavrovsky, Y., Ahn, S. C., Song, C. S., Chatterjee, B., and Roy, A. K. (2000) Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells, Mol. Endocrinol. 14,1162-1174.
14. Chandra, S., Shao, J., Li, J. X., Li, M., Longo, F. M., and Diamond, M. I. (2008)Acommon motiftargets huntingtin and the androgen receptor to the proteasome, J. Biol. Chem. 283, 23950-23955.
15. Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P. A., Sawyers, C. L., and Wu, H. (2007) Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development, Cancer Res. 67, 6083-6091.
16. Dobosy, J. R., Roberts, J. L., Fu, V. X., and Jarrard, D. F. (2007) The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia, J. Urol. 177, 822-831.
17. Hieronymus, H., Lamb, J., Ross, K. N., Peng, X. P., Clement, C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S. M., Maloney, K. N., Clardy, J., Hahn, W. C., Chiosis, G., and Golub, T. R. (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators, Cancer Cell 10, 321-330.
18. Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., and Sawyers, C. L. (2004) HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability, Cancer Cell 6, 517-527.
19. Solit, D. B., Scher, H. I., and Rosen, N. (2003) Hsp90 as a therapeutic targetin prostate cancer, Semin. Oncol. 30, 709-716.
20. Klein, K. A., Reiter, R. E., Redula,J., Moradi, H.,Zhu,X. L., Brothman, A. R., Lamb, D. J., Marcelli, M., Belldegrun, A., Witte, O. N., and Sawyers, C. L. (1997) Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice, Nat. Med. 3, 402-408.
21. Estebanez-Perpina, E., Arnold, L. A., Nguyen, P., Rodrigues, E. D., Mar, E., Bateman, R., Pallai, P., Shokat, K. M., Baxter, J. D., Guy, R. K., Webb, P., and Fletterick, R. J. (2007) A surface on the androgen receptor that allosterically regulates coactivator binding, Proc. Natl. Acad. Sci. U.SA. 104,16074-16079.
22. Chou, T. C., and Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv. Enzyme Regul. 22, 27-55.
23. Dvorak, Z., Vrzal, R., Maurel, P., and Ulrichova, J. (2006) Differential effects of selected natural compounds with anti-inflammatory activity on the glucocorticoid receptor and NF-kappaB in HeLa cells, Chem. Biol. Interact. 159,117-128.
24. Eil, C. (1992) Ketoconazole binds to the human androgen receptor, Horm. Metab. Res. 24, 367-370.
25. Duret, C., Daujat-Chavanieu, M., Pascussi, J. M., Pichard-Garcia, L., Balaguer, P., Fabre, J. M., Vilarem, M. J., Maurel, P., and Gerbal-Chaloin, S. (2006) Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor, Mol. Pharmacol. 70, 329-339.
26. Huang, H., Wang, H., Sinz, M., Zoeckler, M., Staudinger, J., Red-inbo, M. R., Teotico, D. G., Locker, J., Kalpana, G. V., and Mani, S. (2007) Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole, Oncogene 26, 258-268.
27. Hiipakka, R. A., Zhang, H. Z., Dai, W., Dai, Q., and Liao, S. (2002) Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols, Biochem. Pharmacol. 63, 1165-1176.
28. Yang, H., Chen, D., Cui, Q. C., Yuan, X., and Dou, Q. P. (2006) Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancergrowth in nude mice, Cancer Res. 66,4758-4765.
29. Yi, T., Yi, Z., Cho, S. G., Luo, J., Pandey, M. K., Aggarwal, B. B., and Liu, M. (2008) Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling, Cancer Res. 68,1843-1850.
30. Williams, C. R., Tabios, R., Linehan, W. M., and Neckers, L. (2007) Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancerxenograft model, J. Urol. 178,1528-1532.
31. Thomas, M., Dadgar, N., Aphale, A., Harrell, J. M., Kunkel, R., Pratt, W. B., and Lieberman, A. P. (2004) Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts, J Biol. Chem. 279, 8389-8395.
32. Blaskovich, M. A., Sun, J., Cantor, A., Turkson, J., Jove, R., and Sebti, S. M. (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice, Cancer Res. 63,1270-1279.
33. Sun, L., Tran, N., Tang, F., App, H., Hirth, P., McMahon, G., and Tang, C. (1998) Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases, J. Med. Chem. 41, 2588-2603.
34. Marcelli, M., Stenoien, D. L., Szafran, A. T., Simeoni, S., Agoulnik, I. U., Weigel, N. L., Moran, T., Mikic, I., Price, J. H., and Mancini, M. A. (2006) Quantifying effects of ligands on androgen receptor nucleartranslocation, intranuclear dynamics, and solubility, J. Cell. Bio-chem. 98, 770-788.
35. Cleutjens, K. B., van Eekelen, C. C., van der Korput, H. A., Brinkmann, A. O., and Trapman, J. (1996) Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter, J. Biol. Chem. 271, 6379-6388.